Latanoprost; Netarsudil Dimesylate Patent Expiration
Latanoprost; Netarsudil Dimesylate is Used for lowering high eye pressure. It was first introduced by Alcon Laboratories Inc
Latanoprost; Netarsudil Dimesylate Patents
Given below is the list of patents protecting Latanoprost; Netarsudil Dimesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rocklatan | US10588901 | Combination therapy | Mar 14, 2034 | Alcon Labs Inc |
| Rocklatan | US11020385 | Combination therapy | Mar 14, 2034 | Alcon Labs Inc |
| Rocklatan | US11185538 | Compositions for treating glaucoma or reducing intraocular pressure | Mar 14, 2034 | Alcon Labs Inc |
| Rocklatan | US11197853 | Combination therapy | Mar 14, 2034 | Alcon Labs Inc |
| Rocklatan | US9415043 | Combination therapy | Mar 14, 2034 | Alcon Labs Inc |
| Rocklatan | US9931336 | Combination therapy | Mar 14, 2034 | Alcon Labs Inc |
| Rocklatan | US9993470 | Combination therapy | Mar 14, 2034 | Alcon Labs Inc |
| Rocklatan | US8394826 | Dual mechanism inhibitors for the treatment of disease | Nov 10, 2030 | Alcon Labs Inc |
| Rocklatan | US10174017 | Dual mechanism inhibitors for the treatment of disease | Jan 27, 2030 | Alcon Labs Inc |
| Rocklatan | US10654844 | Dual mechanism inhibitors for the treatment of disease | Jan 27, 2030 | Alcon Labs Inc |
| Rocklatan | US11028081 | Dual mechanism inhibitors for the treatment of disease | Jan 27, 2030 | Alcon Labs Inc |
| Rocklatan | US11618748 | Dual mechanism inhibitors for the treatment of disease | Jan 27, 2030 | Alcon Labs Inc |
| Rocklatan | US10532993 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | Jul 11, 2026 | Alcon Labs Inc |
| Rocklatan | US10882840 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | Jul 11, 2026 | Alcon Labs Inc |
| Rocklatan | US11021456 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | Jul 11, 2026 | Alcon Labs Inc |
| Rocklatan | US8450344 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | Jul 11, 2026 | Alcon Labs Inc |
| Rocklatan | US9096569 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | Jul 11, 2026 | Alcon Labs Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Latanoprost; Netarsudil Dimesylate's patents.
Latest Legal Activities on Latanoprost; Netarsudil Dimesylate's Patents
Given below is the list recent legal activities going on the following patents of Latanoprost; Netarsudil Dimesylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Jun, 2024 | US10882840 |
| Correspondence Address Change Critical | 25 Mar, 2024 | US8394826 |
| Correspondence Address Change Critical | 25 Mar, 2024 | US9415043 |
| Correspondence Address Change Critical | 25 Mar, 2024 | US9993470 |
| Correspondence Address Change Critical | 25 Mar, 2024 | US8450344 |
| Correspondence Address Change Critical | 25 Mar, 2024 | US10174017 |
| Correspondence Address Change Critical | 20 Mar, 2024 | US10588901 |
| Correspondence Address Change Critical | 20 Mar, 2024 | US11028081 |
| Correspondence Address Change Critical | 20 Mar, 2024 | US11021456 |
| Correspondence Address Change Critical | 20 Mar, 2024 | US10532993 |
Latanoprost; Netarsudil Dimesylate's Family Patents
